| Cat.No. | Name | Information |
|---|---|---|
| M5728 | Lansoprazole | Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. |
| M4953 | Bafilomycin A1 | Bafilomycin A1 (BafA1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. |
| M55502 | Esomeprazole-d3 sodium | Esomeprazole-d3 sodium |
| M20547 | Rabeprazole Related Compound E | Rabeprazole Related Compound E is the active metabolite of Rabeprazole and an orally active proton pump inhibitor that inhibits gastric acid secretion by interacting with (H+/K+)-ATPase in gastric lining cells. In addition, Rabeprazole Related Compound E significantly inhibits the activity of Helicobacter pylori and can be used in studies related to various digestive disorders. |
| M20514 | Omeprazole Sodium | Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. |
| M20434 | Rabeprazole | Rabeprazole is an orally active proton pump inhibitor that inhibits gastric acid secretion by interacting with (H+/K+)-ATPase in gastric lining cells. In addition, Rabeprazole significantly inhibits the activity of Helicobacter pylori and may be used in studies related to various digestive disorders. |
| M5633 | Pantoprazole sodium | Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
| M5285 | Ilaprazole | Ilaprazole, a substituted benzimidazole, is a new candidate drug that is an H+ /K+ ATPase inhibitor designed for the treatment of gastric ulcers. |
| M3707 | Rabeprazole Sodium | Rabeprazole is a frequently used second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. |
| M3575 | Esomeprazole Magnesium | Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion. |
| M3448 | Esomeprazole Sodium | Esomeprazole Sodium is a sodium salt of esomeprazole that is a potent proton pump inhibitor with an IC50 of 0.076 mg/kg. |
| M3056 | Tenatoprazole | Tenatoprazole is a procompound of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. |
| M2627 | Dexlansoprazole | Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. |
| M1834 | Omeprazole (H 16868) | Omeprazol is a first-in-class proton pump inhibitor (PPI) used in the treatment of dyspepsia, laryngopharyngeal reflux (LPR) and Zollinger–Ellison syndrome. |
| M56565 | Lansoprazole sulfone | Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H+, K+-ATPase. |
| M52724 | Caloxin 2A1 | Caloxin 2A1 is an extracellular plasma membrane Ca2+-ATPase (PMCA) peptide inhibitor. |
| M42247 | CS-526 | CS-526 is a potent, selective, reversible and orally active acid pump antagonist. |
| M29085 | Revaprazan | Revaprazan (SB 641257) is a reversible proton pump inhibitor with significant anti-inflammatory effects. Revaprazan can be used for chronic gastric inflammation research. |
| M29058 | Vonoprazan hydrochloride | Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. |
| M29008 | Abeprazan hydrochloride | Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
